Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESIR-ABLE: Desirudin for Thrombosis Prophylaxis
NCT00913133Phase 4Completed
- Sponsor
- Canyon Pharmaceuticals
- Start
- Mar 2010
- Primary completion
- Jun 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of desirudin in venous thromboembolism (VTE), sponsored by Canyon Pharmaceuticals. Started Mar 2010; status: completed.
02
Drugs
desirudin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT00913133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00913133.